Study Finds Birth Hypoxia May Increase ADHD Likelihood
January 27, 2026
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Aclacinon, Aclacin, Aclacinomycine, Aclaplastin, Jaclacin
Synonyms :
Aclacinomycin A, aclarubicin, Aclarubicina
Class :
Antineoplastic, Cytotoxic Antibiotics, Anthracycline antineoplastic, Topoisomerase inhibitor
Brand Name :
Aclacinon, Aclacin, Aclacinomycine, Aclaplastin, Jaclacin
Synonyms :
Aclacinomycin A, aclarubicin, Aclarubicina
Class :
Antineoplastic, Cytotoxic Antibiotics, Anthracycline antineoplastic, Topoisomerase inhibitor
Dosage Forms & Strengths
Injectable Solution
100 mcg
500 mcg
20 mg
The usual dose that is recommended when initiation of therapy is 175-300 mg/m2, which is given in divided doses for a duration of 3 to 7 days via IV administration with an infusion duration of 30 minutes to one hour
With a single infusion for 3 or 4 weeks, the maintenance dose is 25 -100 mg/m2 via IV
Dose Adjustments
Limited data is available for renal or hepatic impairment
Safety and efficacy are not seen in pediatrics
Refer to the adult dosing
when aclarubicin is combined with ambroxol, there is an increased risk of methemoglobinemia
when aclarubicin is combined with procaine, there is an increased risk of methemoglobinemia
when aclarubicin is combined with meloxicam, there is an increased risk of methemoglobinemia
when aclarubicin is combined with lidocaine, there is an increased risk of methemoglobinemia
when aclarubicin is combined with cocaine, there is an increased risk of methemoglobinemia
Actions and Spectrum:
Actions:
Cytotoxic antibiotic aclarubicin is used against blood malignant disorders and has many anticancer properties by inhibiting the growth of abnormal cancer cells through intercalation by inhibiting RNA synthesis.
Spectrum:
The spectrum of aclarubicin extends to different varieties of malignant blood disorders such as thyroid cancer, acute non-lymphoblastic leukemia, gastric cancer, ovarian cancer, breast cancer, and small cell lung cancer.
Frequency not defined
Bone-Marrow suppression
Vomiting
Nausea
Mucositis
Alopecia
Sore mouth
Hyperuricaemia
Irritant to tissue
Leucopenia
Cardiotoxicity
Myelosuppression
Black Box Warning:
Contact with skin and eyes should be avoided when aclarubicin is administered, and inhalation of this drug is restricted. Monitoring of lab tests such as LFT, blood count, and uric acid level in blood while on aclarubicin.
Contraindication/Caution:
Contraindications
Cautions
Pregnancy consideration:
No data is available regarding the administration of the drug during pregnancy.
Breastfeeding warnings:
No data is available regarding the excretion of drug in breast milk.
Pregnancy category:
Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.
<b>Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: No data is available for the drug under this category.
Pharmacology:
Cytotoxic antibiotic aclarubicin is used against blood malignant disorders and has many anticancer properties by inhibiting the growth of abnormal cancer cells through intercalation by inhibiting RNA synthesis.
Pharmacodynamics:
By intercalation, aclarubicin inhibits RNA synthesis by interacting with topoisomerase I and II, which leads to inhibition of DNA repair and replication and protein synthesis.
Pharmacokinetics:
Absorption
Rapid absorption after IV into tissues.
Distribution
Protein-bound is 43%
The volume of distribution of aclarubicin is 657+-341 L/kg
Metabolism
Metabolized extensively.
Elimination and Excretion
The half-life is 1.4-8.5 hours, terminal half-life: 3 hours.
The drug is excreted in urine as metabolites.
Administration:
Administration of aclarubicin is via Intravenous infusion with the recommended dose depending on the condition of the patient. It is initiated with the usual dose, after which a maintenance dose is administered for a particular duration, depending on the response. The drug is protected from sunlight and stored below 40 degrees Celsius.
Patient information leaflet
Generic Name: aclarubicin
Pronounced: uh-KLAR-uh-bi-sin
Why do we use aclarubicin?
Cytotoxic antibiotic aclarubicin is used against blood malignant disorders and has many anticancer properties by inhibiting the growth of abnormal cancer cells through intercalation by inhibiting RNA synthesis.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
